Jeremy G Chadwick
CIK 1388406 · Chief Operating Officer · last filed 2026-05-27
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$5.75M
Companies
2
Total Filings
31
Lifetime Open-Market Net
-$15.84M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KYMR | Chief Operating Officer | 48,297 | $119.05 | $5.75M | -$15.81M | 12 | 2026-05-27 |
| MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | Sr. VP, Pgm Mgmt and Clin Ops | 23,761 | — | — | -$28.4K | 5 | 2010-03-03 |
Recent Filings · Page 3 of 4
31 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-03-03 | KYMR | Mixed | +23,617 | -$42.1K | EDGAR |
| 2025-03-03 | KYMR | Notice (144) | −1,383 | -$43.4K | EDGAR |
| 2024-05-23 | KYMR | Notice (144) | −2,575 | -$91.9K | EDGAR |
| 2024-05-23 | KYMR | Sell (S) | −2,575 | -$90.1K | EDGAR |
| 2024-03-04 | KYMR | Grant (A) | +13,425 | $0 | EDGAR |
| 2023-05-22 | KYMR | Grant (A) | +33,333 | $0 | EDGAR |
| 2010-03-03 | MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | Grant (A) | +7,908 | $0 | EDGAR |
| 2009-04-14 | MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2009-01-06 | MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | Sell (S) | −4,573 | -$28.4K | EDGAR |
| 2008-02-29 | MADRIGAL PHARMACEUTICALS, INC. (SNTA) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.